RVPHREVIVA PHARMACEUTICALS HOLDINGS, INC.vs its industry peers
A metric-by-metric comparison of REVIVA PHARMACEUTICALS HOLDINGS, INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPHEsta | $5M#1 | — | 0.3x#2 | — | — | 33.6%#2 | — | -130.6%#4 | — | — | -96.0%#2 | — |
| SBFM | $4M#2 | 0.2x#2 | 0.1x#1 | 0.1x#1 | 4.1%#1 | -16.4%#4 | -17.2%#1 | -21.7%#1 | -63.1%#1 | — | — | — |
| GRI | $4M#3 | — | 0.4x#5 | — | -100.0%#3 | -45.7%#7 | — | -116.3%#3 | — | — | — | — |
| CVKD | $4M#4 | — | 1.0x#6 | — | — | -24.3%#5 | — | -323.5%#6 | -585.1%#2 | — | — | — |
| REVB | $4M#5 | 0.0x#1 | 0.4x#4 | — | — | 40.7%#1 | — | -88.5%#2 | — | — | — | — |
| TCRT | $4M#6 | — | 5.8x#7 | 757.1x#2 | -50.0%#2 | 10.8%#3 | -84500.0%#2 | -640.5%#7 | — | — | -35.8%#1 | — |
| BIVIW | $4M#7 | — | 0.4x#3 | — | — | -25.8%#6 | — | -214.9%#5 | -1671.2%#3 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-15.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice